Showing results (221-230 of 299) with videos related to
Sort By:
Pageof 30
Cancer Research and Treatment|October 23, 2023
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort StudyMyeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, et al.BMC Pulmonary Medicine|May 3, 2022
Comparative effectiveness of smartphone healthcare applications for improving quality of life in lung cancer patients: study protocolJang Ho Lee, Jae Hwa Jeong, Wonjun Ji, et al.Biomarker Research|September 13, 2023
Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancerDong Ha Kim, Hyojeong Park, Yun Jung Choi, et al.Current Medical Research and Opinion|December 20, 2019
HL301 versus Umckamin in the treatment of acute bronchitis: a phase III, randomized, controlled, double-blind, multicenter studyWon-Young Kim, Myung Jae Park, Chin Kook Rhee, et al.Thoracic Cancer|April 3, 2018
Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsyHee-Young Yoon, Jae Cheol Lee, Sang-We Kim, et al.Tuberculosis and Respiratory Diseases|January 14, 2014
Causes and predictive factors associated with "diagnosis changed" outcomes in patients notified as tuberculosis cases in a private tertiary hospitalByung Ju Kang, Kyung-Wook Jo, Tai Sun Park, et al.European Journal of Pharmacology|July 5, 2021
Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancerYun Jung Choi, Hyeonjeong Lee, Da-Som Kim, et al.Tuberculosis and Respiratory Diseases|December 8, 2020
Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer PatientsJoon Young Choi, Wonjun Ji, Chang-Min Choi, et al.Oncotarget|March 17, 2016
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerJi Hyun Park, Yun Jung Choi, Seon Ye Kim, et al.Journal for Immunotherapy of Cancer|March 27, 2024
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical studyMyeong Geun Choi, Gun Woo Son, Mi Young Choi, et al.Pageof 30